Lentiviral vectors for treating and modeling human CNS disorders

Journal of Gene Medicine

Volumn 6, Issue 9, 2004, Pages 951-962

  Azzouz, Mimoun ^a   Kingsman, Susan M ^a   Mazarakis, Nicholas D ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

EIAV; Gene therapy; Lentiviral; Modeling; Motor neuron diseases; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; APOPTOSIS INHIBITOR; CILIARY NEUROTROPHIC FACTOR; CYSTAMINE; DOPAMINE; ENZYME INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; LENTIVIRUS VECTOR; LEVODOPA; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; PRODRUG; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE INHIBITOR; RECOMBINANT PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1; TRANSACTIVATOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; BASAL GANGLION; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; EQUINE INFECTIOUS ANEMIA VIRUS; GENE OVEREXPRESSION; GENE TARGETING; GENETIC MODEL; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MOTOR NEURON DISEASE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SAFETY; SIDE EFFECT; SPECIES; SPINAL MUSCULAR ATROPHY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS TYPING;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; HUNTINGTON DISEASE; LENTIVIRUS; MOTOR NEURON DISEASE; PARKINSON DISEASE;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; LENTIVIRUS; PRIMATES;

EID: 13644255422     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.600     Document Type: Review

References (115)

1. Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 2003; 4: 353-364.
2. Martin-Rendon E, Azzouz M, Mazarakis ND. Lentiviral vectors for the treatment of neurodegenerative diseases. Curr Opin Mol Ther 2001; 3: 476-481.
3. Rohll JB, Mitrophanous KA, Martin-Rendon E, et al. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol 2002; 346: 466-500.
4. Deglon N, Aebischer P. Lentiviruses as vectors for CNS diseases. Curr Topics Microbiol Immunol 2002; 261: 191-209.
5. Burkrinsky MI, Sharova N, Dempsey MP, et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci 1992; 89: 6580-6584.
6. Burkrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365: 666-669.
7. Gallay P, Stitt V, Mundy C, et al. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996; 70: 1027-1032.
8. Mazarakis ND, Azzouz M, Rohll JB, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10: 2109-2121.
9. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22: 10 302-10 312.
10. Deglon N, Tseng JL, Bensadoun JC, et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gen Ther 2000; 11: 179-190.
11. Bensadoun JC, Deglon N, Tseng JL, et al. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 2000; 164: 15-24.
12. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-773.
13. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11388.
14. Blomer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641-6649.
15. Bienemann AS, Martin-Rendon E, Cosgrave AS, et al. Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Mol Ther 2003; 7: 588-596.
16. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
17. Negre D, Cosset FL. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 2002; 84: 1161-1171.
18. Mitrophanous K, Yoon S, Rohll J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999; 6: 1808-1818.
19. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
20. Trono D. When accessories turn out to be essential. Nat Med 1998; 4: 1368-1369.
21. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
22. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
23. Wang G, Slepushkin V, Zabner J, et al. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest 1999; 104: R55-62.
24. Stitz J, Muhlebach MD, Blomer U, et al. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. Virology 2001; 291: 191-197.
25. MacKenzie T, Kobinger G, Kootstra N, et al. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002; 6: 349-358.
26. Watson DJ, Kobinger GP, Passini MA, et al. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 2002; 5: 528-537.
27. Kobinger G, Weiner D, Yu Q, Wilson J. Filovirus-pseudotyped lentiviral. vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19: 225-230.
28. Wong LF, Azzouz M, Walmsley LE, et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 2004; 9: 101-111.
29. O'Rourke JP, Hiraragi H, Urban K, et al. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. Mol Ther 2003; 7: 632-639.
30. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
31. Kirik D, Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 2003; 26: 386-392.
32. Burright EN, Clark HB, Servadio A, et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 1995; 82: 937-948.
33. Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002; 35: 843-854.
34. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
35. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
36. Wong PC, Borchelt DR. Motor neuron disease caused by mutations in superoxide dismutase 1. Curr Opin Neurol 1995; 8 294-301.
37. Ripps ME, Huntley GW, Hof PR, et al. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 1995; 92: 689-693.
38. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338.
39. Hsieh-Li HM, Chang JG, Jong YJ, et al. A mouse model for spinal muscular atrophy. Nat Genet 2000; 24: 66-70.
40. Monani UR, Coovert DD, Burghes AH. Animal models of spinal muscular atrophy. Hum Mol Genet 2000; 9: 2451-2457.
41. Frugier T, Tiziano FD, Cifuentes-Diaz C, et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet 2000; 9: 849-858.
42. Blomer U, Kafri T, Randolph-Moore L, et al. Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. Proc Natl Acad Sci U S A 1998; 95: 2603-2608.
43. Spillantini M, Crowther R, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998; 95: 6469-6473.
44. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
45. Polymeropoulos M, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
46. Barker RA, Dunnett SB. Functional integration of neural grafts in Parkinson's disease. Nat Neurosci 1999; 2: 1047-1048.
47. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2: 137-140.
48. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
49. Tenenbaum L, Chtarto A, Lehtonen E, et al. Neuroprotective gene therapy for Parkinson's disease. Curr Gene Ther 2002; 2: 451-483.
50. Burton EA, Glorioso JC, Fink DJ. Gene therapy progress and prospects: Parkinson's disease. Gene Ther 2003; 10: 1721-1727.
51. Shen Y, Muramatsu SI, Ikeguchi K. et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hyroxylase, aromatic L-amino-acid decarboxylase and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000; 11 1509-1519.
52. Muramatsu S. Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002; 13: 345-354.
53. Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 1999; 92: 185-196.
54. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164: 2-14.
55. Sanchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther 2001; 4: 324-330.
56. Oligino T, Poliani PL, Wang Y, et al. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther 1998; 5: 491-496.
57. Pollock R, Issner R, Zoller K, et al. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci U S A 2000; 97: 13 221-13 226.
58. Vigna E, Cavalieri S, Ailles L, et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 2002; 5: 252-261.
59. Ross C. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002; 35: 819-822.
60. Vonsattel J, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
61. Haque N, Isacson O. Antisense gene therapy for neurodegenerative disease? Exp Neurol 1997; 144: 139-146.
62. Phylactou L, Darrah C, Wood MJ. Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat Genet 1998; 18: 378-381.
63. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200.
64. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-1010.
65. de Almeida LP, Zala D, Aebischer P, Deglon N. Neuroprotective effect of a cntf-expressing lentiviral vector in the quinolinic acid rat model of huntington's disease. Neurobiol Dis 2001; 8: 433-446.
66. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8: 143-149.
67. Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001; 58: 512-515.
68. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991; 66: 54-82.
69. Mulder DW. Clinical limits of amyotrophic lateral sclerosis. Adv Neurol 1982; 36: 15-22.
70. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 364: 362.
71. Julien J. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 2001; 104: 581-591.
72. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-819.
73. Rothstein JD, Bristol LA, Hosler B, et al. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A 1994; 91: 4155-4159.
74. Rabizadeh S, Gralla EB, Borchelt DR, et al. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc Natl Acad Sci U S A 1995; 92: 3024-3028.
75. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997; 56: 523-530.
76. Ghadge GD, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci 1997; 17: 8756-8766.
77. Pasinelli P, Borchelt DR, Houseweart MK, et al. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci U S A 1998; 95: 15 763-15 768.
78. Kostic V, Jackson-Lewis V, de Bilbao F, et al. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-562.
79. Friedlander RM, Brown RH, Gagliardini V, et al. Inhibition of ICE slows ALS in mice. Nature 1997; 388: 31.
80. Perrelet D, Ferri A, MacKenzie AE, et al. IAP family proteins delay motoneuron cell death in vivo. Eur J Neurosci 2000; 12: 2059-2067.
81. Azzouz M, Hottinger A, Paterna JC, et al. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet 2000; 9: 803-811.
82. Haase G, Pettmann B, Vigne E, et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. J Neurol Sci 1998; 160(Suppl 1): S97-105.
83. Hottinger AF, Azzouz M, Deglon N, et al. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 2000; 20: 5587-5593.
84. Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22: 6920-6928.
85. Kaspar B, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842.
86. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-424.
87. Tuszynski MH. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 2002; 1: 51-57.
88. Aebischer P, Ridet J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci 2001; 24: 533-540.
89. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978; 15 409-413.
90. Melki J, Lefebvre S, Burglen L, et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science 1994; 264: 1474-1477.
91. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155-165.
92. Bussaglia E, Clermont O, Tizzano E, et al. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet 1995; 11: 335-337.
93. Battaglia G, Princivalle A, Forti F, et al. Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum Mol Genet 1997; 6: 1961-1971.
94. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16: 265-269.
95. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996; 15: 3555-3565.
96. Schrank B, Gotz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 1997; 94: 9920-9925.
97. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001; 19: 640-644.
98. Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54: 647-654.
99. Kirik D, Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 2003; 26: 386-392.
100. Rubinsztein D. Lessons from animal models of Huntington's disease. Trends Genet 2002; 18: 202-209.
101. Senut MC, Suhr ST, Kaspar B, Gage FH. Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J Neurosci 2000; 20: 219-229.
102. de Almeida L, Ross C, Zala D, et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002; 22: 3473-3483.
103. Déglon N, Regulier E, Palfi S, et al. Intraneural aggregates, striatal dysfunction and behavioral deficits following lentiviral overexpression of mutated huntingtin in rats and non-human primates. ASGT: Washington, USA 2003.
104. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000; 20: 6021-6029.
105. Kahle P, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000; 20: 6365-6373.
106. Feany M, Bender W. Drosophila model of Parkinson's disease. Nature 2000; 404: 394-398.
107. Lo Bianco C, Ridet J, Schneider B, et al. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002; 99: 10813-10818.
108. Figlewicz D, Krizus A, Martinoli M, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757-1761.
109. La Spada A, Wilson E, Lubahn D, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77-79.
110. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
111. Kitada T, Asakawa S. Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
112. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
113. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
114. Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003; 33 85-89.
115. Lin CL, Bristol LA, An L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20: 589-602.